<p><strong>Pediatric Use</strong>: The safety and effectiveness of Tofacitinib in pediatric patients have not been established.<br />
<br />
<strong>Geriatric Use</strong>: The frequency of serious infection among Tofacitinib-treated subjects 65 years of age and older was higher than among those under the age of 65. As there is a higher incidence of infections in the elderly population in general, caution should be used when treating the elderly.<br />
<br />
<strong>Moderate and severe renal impairment or moderate hepatic impairment</strong>: half the total daily dosage recommended for patients with normal renal and hepatic function.</p>